Combination therapies involving lenalidomide have revolutionized the treatment of multiple myeloma. When paired with drugs like dexamethasone or monoclonal antibodies such as daratumumab, lenalidomide enhances treatment efficacy by targeting cancer cells through multiple mechanisms. These combinations not only improve response rates but also extend progression-free survival, even in patients with advanced disease. The synergistic effects of such regimens make them a preferred choice in many treatment plans. Considering the cost of lenalidomide is essential when discussing combination therapies, as treatment affordability directly impacts adherence. Patients should work with their healthcare team to explore financial support options and ensure continuity of care.